Abstract
Introduction Data quality improvements have aimed to align national reporting systems for Ministry of Health (MISAU) and PEPFAR. For example, in 2019 the patient Master Card improved systematic data collection process and sites were selected for intensified support including data quality activities (AJUDA). This study aims to compare reported data between MISAU and PEPAFR to understand data alignment trends.
Methods The annual number of PLHIV on ART, newly initiating ART and HIV status in first ANC visit as reported by MISAU and PEPFAR were compared for 2017-2023. The absolute difference was calculated as MISAU-reported number minus PEPFAR-reported number; proportional absolute difference as the absolute difference over the MISAU-reported number and assessed the slope of the difference over time.
Results During 2017–2023, median absolute difference for PLHIV on ART was 104,940 (range = 154,901 [2018] to 1,598 [2020]), and median proportional difference was 5.0% (range = 0.1% [2020] to 12.8% [2018]), with a trend towards improved concordance. A similar trend was found in positive HIV status at first ANC (10.4% [2017] to 0.0% [2023]), as well as with newly initiated on ART (2.7% [2017] to 0.3% [2023]).
Conclusion In the three indicators analyzed, there were improvements in data alignment between the years of 2017 and 2023, with increased alignment in different years and for different reasons. Continued improvements will support programming and increase certainty for tracking progress toward the UNAIDS 95-95-95 goals to end HIV.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This manuscript has been supported by the Presidents Emergency Plan for AIDS Relief (PEPFAR), through the Centers for Disease Control and Prevention (CDC), The findings and conclusions in this manuscript are those of the author(s) and do not necessarily represent the official position of the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used for this data set is available from the PEPFAR Monitoring, Evaluation, and Reporting (MER) Database or from the publicly available Ministry of Health HIV Annual Reports
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.